[author: J. Steven Rutt]
The September 3, 2012 issue of C&EN discusses what it calls an “onslaught of nanotech drugs coming down the pike” for FDA review. See article entitled “Mapping Nanotech Drugs’ Landscape,” pp. 46, 48.
The FDA is generating a database for nanotech drugs and currently has 158 entries according to the article. The leading application area is cancer treatment (38%). Most are developed to be administered intravenously (56%). The leading types of formulation are liposomes (39%) and nanoparticles (27%).
The FDA will hold a public workshop in the coming months to get input from stakeholders for how to improve the review process.
The US patent literature confirms the role of nanotechnology innovation in cancer treatment. Of the currently published nanotechnology class 977 patent filings (there are 13,814 of them), 1.9% of them refer to cancer in the title or abstract. Considering the breadth of nanotechnology and bio nanotechnology, this is a significant fraction. Also, 4.3% of them refer to cancer in the title, abstract, or claim. Finally, 14.3% of them mention cancer in the patent somewhere.